These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 2526109)

  • 41. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Microbiological-clinical study on the efficacy of a new antibiotic: teicoplanin].
    Martinetto P; Gariglio M; Malcangi A; Cavallo GP
    G Batteriol Virol Immunol; 1985; 78(1-6):86-94. PubMed ID: 2943627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Teicoplanin in the therapy of staphylococcal neuroshunt infections.
    Maserati R; Cruciani M; Azzini M; Carnevale C; Suter F; Concia E
    Int J Clin Pharmacol Res; 1987; 7(3):207-13. PubMed ID: 2954919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Debbag R; Paganini H; Gómez S; Casimir L; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients.
    Testore GP; Uccella I; Sarrecchia C; Mattei A; Impagliazzo A; Sordillo P; Andreoni M
    J Chemother; 2000 Oct; 12(5):412-5. PubMed ID: 11128561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Susceptibility of Clostridium difficile strains to teicoplanin and ramoplanin].
    Dworczyński A; Martirosian G; Meisel-Mikołajczyk F
    Med Dosw Mikrobiol; 1993; 45(4):483-6. PubMed ID: 8189828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
    Drago L; De Vecchi E; Nicola L; Gismondo MR
    BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P; Aoun M; Meunier F
    Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infections due to gram-positive organisms in children: possible role for teicoplanin.
    Dagan R; Einhorn M; Howard CB; Williams AH
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():37-41. PubMed ID: 1829075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children.
    Schaison G; Baruchel A; Arlet G
    Br J Haematol; 1990 Dec; 76 Suppl 2():24-6. PubMed ID: 2149047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
    Martino P; Venditti M; Micozzi A; Brandimarte C; Gentile G; Santini C; Serra P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1329-34. PubMed ID: 2529815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of Clostridium difficile-associated disease with teicoplanin.
    de Lalla F; Privitera G; Rinaldi E; Ortisi G; Santoro D; Rizzardini G
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1125-7. PubMed ID: 2528941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Options and limitations of teicoplanin in febrile granulocytopenic patients.
    De Pauw BE; Novakova IR; Donnelly JP
    Br J Haematol; 1990 Dec; 76 Suppl 2():1-5. PubMed ID: 2149042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of gram-positive therapy in the neutropenic patient.
    Menichetti F; Del Favero A
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():51-60. PubMed ID: 1829077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients.
    Nováková IR; Donnelly JP; Verhagen CS; De Pauw BE
    J Antimicrob Chemother; 1990 Jun; 25(6):985-93. PubMed ID: 2142486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial.
    Weinberg WG
    South Med J; 1993 Aug; 86(8):891-7. PubMed ID: 8351549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson R
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.
    Gilbert DN; Wood CA; Kimbrough RC
    Antimicrob Agents Chemother; 1991 Jan; 35(1):79-87. PubMed ID: 1826594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.